Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Mass cytometry reveals species-specific differences and a new level of complexity for immune cells in the prostate.

Fox JJ, Navarro HI, Hashimoto T, Garcia AJ, Goldstein AS.

Am J Clin Exp Urol. 2019 Aug 15;7(4):281-296. eCollection 2019.

2.

Expansion of Luminal Progenitor Cells in the Aging Mouse and Human Prostate.

Crowell PD, Fox JJ, Hashimoto T, Diaz JA, Navarro HI, Henry GH, Feldmar BA, Lowe MG, Garcia AJ, Wu YE, Sajed DP, Strand DW, Goldstein AS.

Cell Rep. 2019 Aug 6;28(6):1499-1510.e6. doi: 10.1016/j.celrep.2019.07.007.

3.

Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.

Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Arevalillo JM, Ferrer-Gómez M, Navarro H, Maín P, Espinosa E, Pinto Á, Vara JÁF.

BMC Cancer. 2019 Jun 28;19(1):636. doi: 10.1186/s12885-019-5858-z.

4.

A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.

Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, Arevalillo JM, Zapater-Moros A, Ferrer-Gómez M, Díaz-Almirón M, López-Vacas R, Navarro H, Maín P, Feliú J, Zamora P, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2019 Feb 7;9(1):1538. doi: 10.1038/s41598-018-38364-y.

5.

Factors predicting early dropout from dialectical behaviour therapy in individuals with borderline personality disorder.

Carmona I Farrés C, Pascual JC, Elices M, Navarro H, Martin Blanco A, Soler J.

Actas Esp Psiquiatr. 2018 Nov;46(6):226-33. Epub 2018 Nov 1.

6.

Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).

Ondachi PW, Kormos CM, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Fennell TR, Snyder RW, Carroll FI.

J Med Chem. 2018 Sep 13;61(17):7525-7545. doi: 10.1021/acs.jmedchem.8b00673. Epub 2018 Aug 29.

7.

Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

Kormos CM, Ondachi PW, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Fennell TR, Snyder RW, Carroll FI.

J Med Chem. 2018 Sep 13;61(17):7546-7559. doi: 10.1021/acs.jmedchem.8b00674. Epub 2018 Aug 29.

8.

Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer.

Zapater-Moros A, Gámez-Pozo A, Prado-Vázquez G, Trilla-Fuertes L, Arevalillo JM, Díaz-Almirón M, Navarro H, Maín P, Feliú J, Zamora P, Espinosa E, Fresno Vara JÁ.

Oncotarget. 2018 Jun 12;9(45):27586-27594. doi: 10.18632/oncotarget.25496. eCollection 2018 Jun 12.

9.

HoxB13 mediates AR-V7 activity in prostate cancer.

Navarro HI, Goldstein AS.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6528-6529. doi: 10.1073/pnas.1808196115. Epub 2018 Jun 11. No abstract available.

10.

Molecular characterization of breast cancer cell response to metabolic drugs.

Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, Díaz-Almirón M, Prado-Vázquez G, Zapater-Moros A, Navarro H, Aras-López R, Dapía I, López-Vacas R, Nanni P, Llorente-Armijo S, Arias P, Borobia AM, Maín P, Feliú J, Espinosa E, Fresno Vara JÁ.

Oncotarget. 2018 Jan 8;9(11):9645-9660. doi: 10.18632/oncotarget.24047. eCollection 2018 Feb 9.

11.

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

Raleigh MD, Peterson SJ, Laudenbach M, Baruffaldi F, Carroll FI, Comer SD, Navarro HA, Langston TL, Runyon SP, Winston S, Pravetoni M, Pentel PR.

PLoS One. 2017 Dec 1;12(12):e0184876. doi: 10.1371/journal.pone.0184876. eCollection 2017.

12.

Urothelial cancer proteomics provides both prognostic and functional information.

de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D.

Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.

13.

Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients.

Molins C, Carceller-Sindreu M, Navarro H, Carmona C, Piñeiro M, Martínez E, Álvarez E, Portella MJ.

Psychiatry Res. 2017 Dec;258:153-157. doi: 10.1016/j.psychres.2017.10.010. Epub 2017 Oct 3.

PMID:
29024893
14.

Functional proteomics outlines the complexity of breast cancer molecular subtypes.

Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H, Grossmann J, Gayá Moreno F, Gómez Rioja R, Prado-Vázquez G, Zapater-Moros A, Main P, Feliú J, Martínez Del Prado P, Zamora P, Ciruelos E, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2017 Aug 30;7(1):10100. doi: 10.1038/s41598-017-10493-w.

15.

Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists.

Kormos CM, Ondachi PW, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Carroll FI.

ACS Med Chem Lett. 2017 May 25;8(7):742-745. doi: 10.1021/acsmedchemlett.7b00115. eCollection 2017 Jul 13.

16.

Carlosrosaea hohenbergiae sp. nov. and Carlosrosaea aechmeae sp. nov., two tremellaceous yeasts isolated from bromeliads in north-eastern Brazil.

Felix CR, Navarro HMC, Paulino GVB, Broetto L, Landell MF.

Int J Syst Evol Microbiol. 2017 Jun;67(6):1752-1757. doi: 10.1099/ijsem.0.001856. Epub 2017 Jun 14.

PMID:
28613149
17.

Design, Synthesis, and Biological Evaluation of Structurally Rigid Analogues of 4-(3-Hydroxyphenyl)piperidine Opioid Receptor Antagonists.

Runyon SP, Kormos CM, Gichinga MG, Mascarella SW, Navarro HA, Deschamps JR, Imler GH, Carroll FI.

J Org Chem. 2016 Nov 4;81(21):10383-10391. Epub 2016 Aug 2.

18.

Synthesis, Nicotinic Acetylcholine Receptor Binding, and in Vitro and in Vivo Pharmacological Properties of 2'-Fluoro-(substituted thiophenyl)deschloroepibatidine Analogues.

Ondachi PW, Castro AH, Sherman B, Luetje CW, Damaj MI, Mascarella SW, Navarro HA, Carroll FI.

ACS Chem Neurosci. 2017 Jan 18;8(1):115-127. doi: 10.1021/acschemneuro.6b00252. Epub 2016 Oct 20.

PMID:
27726337
19.

A network approach to discerning the identities of C. elegans in a free moving population.

Winter PB, Brielmann RM, Timkovich NP, Navarro HT, Teixeira-Castro A, Morimoto RI, Amaral LA.

Sci Rep. 2016 Oct 11;6:34859. doi: 10.1038/srep34859.

20.

Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres.

Kormos CM, Gichinga MG, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Carroll FI.

Bioorg Med Chem. 2016 Aug 15;24(16):3842-8. doi: 10.1016/j.bmc.2016.06.029. Epub 2016 Jun 15.

21.

Synthesis, Nicotinic Acetylcholine Binding, and in Vitro and in Vivo Pharmacological Properties of 2'-Fluoro-(carbamoylpyridinyl)deschloroepibatidine Analogues.

Ondachi PW, Castro AH, Luetje CW, Wageman CR, Marks MJ, Damaj MI, Mascarella SW, Navarro HA, Carroll FI.

ACS Chem Neurosci. 2016 Jul 20;7(7):1004-12. doi: 10.1021/acschemneuro.6b00107. Epub 2016 May 19.

PMID:
27166021
22.

Corrigendum to "A selective delta opioid receptor antagonist based on a stilbene core" [Bioorg. Med. Chem. Lett. 25 (2015) 5532-5535].

Hartung AM, Navarro HA, Wiemer DF, Neighbors JD.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1645. doi: 10.1016/j.bmcl.2016.02.014. Epub 2016 Feb 11. No abstract available.

PMID:
28750745
23.

Dynamics and heterogeneity of a fate determinant during transition towards cell differentiation.

Peláez N, Gavalda-Miralles A, Wang B, Navarro HT, Gudjonson H, Rebay I, Dinner AR, Katsaggelos AK, Amaral LA, Carthew RW.

Elife. 2015 Nov 19;4. pii: e08924. doi: 10.7554/eLife.08924.

24.

A selective delta opioid receptor antagonist based on a stilbene core.

Hartung AM, Navarro HA, Wiemer DF, Neighbors JD.

Bioorg Med Chem Lett. 2015 Dec 1;25(23):5532-5. doi: 10.1016/j.bmcl.2015.10.059. Epub 2015 Oct 23. Erratum in: Bioorg Med Chem Lett. 2016 Mar 15;26(6):1645. Bioorg Med Chem Lett. 2016 Mar 15;26(6):1645.

25.

Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).

Chang SD, Brieaddy LE, Harvey JD, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA, Decker AM, McElhinny CJ Jr, Zhong D, Peterson EE, Navarro HA, Bruchas MR, Carroll FI.

ACS Chem Neurosci. 2015 Dec 16;6(12):1956-64. doi: 10.1021/acschemneuro.5b00208. Epub 2015 Sep 30.

26.

Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.

Carroll FI, Gichinga MG, Kormos CM, Maitra R, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA.

Bioorg Med Chem. 2015 Oct 1;23(19):6379-88. doi: 10.1016/j.bmc.2015.08.025. Epub 2015 Aug 25.

27.

Synthesis, nicotinic acetylcholine receptor binding, in vitro and in vivo pharmacology properties of 3'-(substituted pyridinyl)-deschloroepibatidine analogs.

Ondachi PW, Ye Z, Castro AH, Luetje CW, Damaj MI, Mascarella SW, Navarro HA, Carroll FI.

Bioorg Med Chem. 2015 Sep 1;23(17):5693-701. doi: 10.1016/j.bmc.2015.07.021. Epub 2015 Jul 17.

28.

Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.

Chang SD, Mascarella SW, Spangler SM, Gurevich VV, Navarro HA, Carroll FI, Bruchas MR.

Mol Pharmacol. 2015 Sep;88(3):502-11. doi: 10.1124/mol.115.099150. Epub 2015 Jul 1.

29.

In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.

Carroll FI, Navarro HA, Mascarella SW, Castro AH, Luetje CW, Wageman CR, Marks MJ, Jackson A, Damaj MI.

ACS Chem Neurosci. 2015 Jun 17;6(6):920-6. doi: 10.1021/acschemneuro.5b00077. Epub 2015 Apr 30.

30.

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.

Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, Grossmann J, Castaneda CA, Main P, Díaz-Almirón M, Espinosa E, Ciruelos E, Fresno Vara JÁ.

Cancer Res. 2015 Jun 1;75(11):2243-53. doi: 10.1158/0008-5472.CAN-14-1937. Epub 2015 Apr 16.

31.

Enhanced field-of-view integral imaging display using multi-Köhler illumination.

Tolosa Á, Martinez-Cuenca R, Navarro H, Saavedra G, Martínez-Corral M, Javidi B, Pons A.

Opt Express. 2014 Dec 29;22(26):31853-63. doi: 10.1364/OE.22.031853.

PMID:
25607153
32.

Morphology, cell viability, karyotype, expression of surface markers and plasticity of three human primary cell line cultures before and after the cryostorage in LN2 and GN2.

Del Pino A, Ligero G, López MB, Navarro H, Carrillo JA, Pantoll SC, Díaz de la Guardia R.

Cryobiology. 2015 Feb;70(1):1-8. doi: 10.1016/j.cryobiol.2014.10.011. Epub 2014 Nov 8.

PMID:
25445570
33.

[The opinion of teachers about tutorial problem based learning].

Navarro H N, Zamora S J.

Rev Med Chil. 2014 Aug;142(8):989-97. doi: 10.4067/S0034-98872014000800006. Spanish.

34.

Design, synthesis, and biological evaluation of (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-isoquinolinecarboxamide (JDTic) analogues: in vitro pharmacology and ADME profile.

Kormos CM, Gichinga MG, Maitra R, Runyon SP, Thomas JB, Brieaddy LE, Mascarella SW, Navarro HA, Carroll FI.

J Med Chem. 2014 Sep 11;57(17):7367-81. doi: 10.1021/jm5008177. Epub 2014 Aug 25.

35.

Three-dimensional display by smart pseudoscopic-to-orthoscopic conversion with tunable focus.

Martínez-Corral M, Dorado A, Navarro H, Saavedra G, Javidi B.

Appl Opt. 2014 Aug 1;53(22):E19-25. doi: 10.1364/AO.53.000E19.

PMID:
25090349
36.

Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A.

Vasiljevik T, Groer CE, Lehner K, Navarro H, Prisinzano TE.

J Nat Prod. 2014 Aug 22;77(8):1817-24. doi: 10.1021/np5002048. Epub 2014 Jul 30.

37.

Aporphinoid antagonists of 5-HT2A receptors: further evaluation of ring A substituents and the size of ring C.

Ponnala S, Kapadia N, Navarro HA, Harding WW.

Chem Biol Drug Des. 2014 Nov;84(5):558-66. doi: 10.1111/cbdd.12345. Epub 2014 Jun 3.

38.

Effect of the 3- and 4-methyl groups on the opioid receptor properties of N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines.

Kormos CM, Cueva JP, Gichinga MG, Runyon SP, Thomas JB, Brieaddy LE, Mascarella SW, Gilmour BP, Navarro HA, Carroll FI.

J Med Chem. 2014 Apr 10;57(7):3140-7. doi: 10.1021/jm500184j. Epub 2014 Mar 26.

39.

Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.

Ponnala S, Gonzales J, Kapadia N, Navarro HA, Harding WW.

Bioorg Med Chem Lett. 2014 Apr 1;24(7):1664-7. doi: 10.1016/j.bmcl.2014.02.066. Epub 2014 Mar 4.

40.

Bupropion and bupropion analogs as treatments for CNS disorders.

Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI.

Adv Pharmacol. 2014;69:177-216. doi: 10.1016/B978-0-12-420118-7.00005-6. Review.

PMID:
24484978
41.

Stilbenes as κ-selective, non-nitrogenous opioid receptor antagonists.

Hartung AM, Beutler JA, Navarro HA, Wiemer DF, Neighbors JD.

J Nat Prod. 2014 Feb 28;77(2):311-9. doi: 10.1021/np4009046. Epub 2014 Jan 23.

42.

Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-3'-(substituted pyridinyl)-7-deschloroepibatidine analogues.

Ondachi PW, Castro AH, Bartkowiak JM, Luetje CW, Damaj MI, Mascarella SW, Navarro HA, Carroll FI.

J Med Chem. 2014 Feb 13;57(3):836-48. doi: 10.1021/jm401602p. Epub 2014 Jan 28.

43.

Palladium-catalyzed transformations of salvinorin A, a neoclerodane diterpene from Salvia divinorum.

Riley AP, Day VW, Navarro HA, Prisinzano TE.

Org Lett. 2013 Dec 6;15(23):5936-9. doi: 10.1021/ol4027528. Epub 2013 Nov 18.

44.

Does increasing community and liquor licensees' awareness, police activity, and feedback reduce alcohol-related violent crime? A benefit-cost analysis.

Navarro HJ, Shakeshaft A, Doran CM, Petrie DJ.

Int J Environ Res Public Health. 2013 Oct 28;10(11):5490-506. doi: 10.3390/ijerph10115490.

45.

4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist.

Carroll FI, Gichinga MG, Williams JD, Vardy E, Roth BL, Mascarella SW, Thomas JB, Navarro HA.

J Med Chem. 2013 Nov 14;56(21):8826-33. doi: 10.1021/jm401250s. Epub 2013 Nov 5.

46.

Exploring correlations in gene expression microarray data for maximum predictive-minimum redundancy biomarker selection and classification.

Arevalillo JM, Navarro H.

Comput Biol Med. 2013 Oct;43(10):1437-43. doi: 10.1016/j.compbiomed.2013.07.005. Epub 2013 Jul 13.

PMID:
24034735
47.

Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists.

Kormos CM, Jin C, Cueva JP, Runyon SP, Thomas JB, Brieaddy LE, Mascarella SW, Navarro HA, Gilmour BP, Carroll FI.

J Med Chem. 2013 Jun 13;56(11):4551-67. doi: 10.1021/jm400275h. Epub 2013 May 16.

48.

Multispectral integral imaging acquisition and processing using a monochrome camera and a liquid crystal tunable filter.

Latorre-Carmona P, Sánchez-Ortiga E, Xiao X, Pla F, Martínez-Corral M, Navarro H, Saavedra G, Javidi B.

Opt Express. 2012 Nov 5;20(23):25960-9. doi: 10.1364/OE.20.025960.

PMID:
23187411
49.

Synthesis and nicotinic acetylcholine receptor in vitro and in vivo pharmacological properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues of 2'-fluoro-3'-(4-nitrophenyl)deschloroepibatidine.

Ondachi P, Castro A, Luetje CW, Damaj MI, Mascarella SW, Navarro HA, Carroll FI.

J Med Chem. 2012 Jul 26;55(14):6512-22. doi: 10.1021/jm300575y. Epub 2012 Jul 11.

50.

Finite element analysis of maxillary bone stress caused by Aramany Class IV obturator prostheses.

Miyashita ER, Mattos BS, Noritomi PY, Navarro H.

J Prosthet Dent. 2012 May;107(5):336-42. doi: 10.1016/S0022-3913(12)60086-9.

PMID:
22546312

Supplemental Content

Loading ...
Support Center